medigraphic.com
ISSN 1561-3054 (Electronic)

2020, Number 3

<< Back Next >>

Rev Cubana Med Trop 2020; 72 (3)

Extraintestinal Escherichia coli, antimicrobial resistance and betalactamase production in Cuban isolates

Quiñones PD, Betancourt GY, Carmona CY, Pereda NN, Álvarez VS, Soe aung M, Kobayashi N

Language: Spanish
References: 39
Page: 1-18
PDF size: 542.70 Kb.


ABSTRACT

Introduction: Extraintestinal Escherichia coli is one of the main pathogens causing infections associated to health care, with a high impact on health, due to its morbidity and mortality.
Objective: Describe the clinical behavior of extraintestinal E. coli in Cuban hospitals, and determine antimicrobial resistance and betalactamase production.
Methods: A descriptive cross-sectional study was conducted at the Microbiology National Reference Laboratory of Pedro Kourí Tropical Medicine Institute from May 2017 to June 2018. The study included 119 Escherichia coli isolates causing extraintestinal infections in 30 hospitals from various geographic areas in the country. Identification was based on the API 20E system, and determination of in vitro susceptibility to 16 antimicrobials on the automated system VITEK-2 and the disk diffusion method, except for colistin, for which the disk elution method was used. Phenotypical detection was also performed of AmpC extended-spectrum betalactamase and metallobetalactamase.
Results: The most common disorders caused by extraintestinal E. coli were surgical wound infection (23.5%), bloodstream infection (20.7%), respiratory infections (17.6%), skin infections (16.8%) and urinary tract infection (12.6%). A predominance was found of resistance to betalactams, which ranged between 61.3% y 89.1%, whereas 79.8% and 80.5% of the isolates were resistant to trimethoprim / sulfamethoxazole and tetracycline, respectively. Amikacin, fosfomycin, colistin and carbapenemics displayed greater in vitro activity. 43.7% produced extended spectrum betalactamases, 7.6% plasmid AmpC and 0.8% metallobetalactamase.
Conclusions: The low sensitivity of extraintestinal E. coli isolates to first-line antimicrobials and the detection of a metallobetalactamase producing isolate are evidence of the need to maintain continuous surveillance of this pathogen, for which the treatment options are ever more restricted.


REFERENCES

  1. Daga AP, Koga VL, Soncini JGM, de Matos CM, Perugini MRE, Pelisson M, et al. Escherichia coli Bloodstream Infections in Patients at a University Hospital: Virulence Factors and Clinical Characteristics. Front Cell Infect Microbiol. 2019;9:191. DOI: 10.3389/fcimb.2019.00191

  2. Pitout J. Extraintestinal pathogenic Escherichia coli: an update on antimicrobial resistance, laboratory diagnosis and treatment. Expert Rev Anti Infect Ther. 2012;10(10):1165-76.

  3. Garza-González E, Mendoza-Ibarra S, Llaca-Díaz J. Molecular characterization and antimicrobial susceptibility of extended spectrum belactamase producing Enterobacteriaceae isolates at a tertiary care centre in Monterrey, México. J Med Microbiol. 2011;60:84-90.

  4. Solé M, Pitart C, Roca I, Fàbrega A, Salvador P, Muñoz L, et al. First description of an Escherichia coli strain producing NDM-1 carbapenemase in Spain. Antimicrob Agents Chemother. 2011;55:4402-4.

  5. Gür D, Gülay Z, Akan OA, Akta Z, Kayacan CB, Cakici O, et al. Resistance to newer betalactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study. Mikrobiyol Bul. 2008;42(4):537-44.

  6. Tacconelli E, Magrini N. Global priority list of antibiotic- resistant bacteria to guide research, discovery, and development of new antibiotics. Geneva: World Health Organization; 27 February 2017. [acceso: 23/07/2020]. Disponible en: Disponible en: https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/

  7. Sistema Mundial de Vigilancia de la Resistencia a los Antimicrobianos. Manual para la primera fase de implementación [Global antimicrobial resistance surveillance system: manual for early implementation]. Ginebra: Organización Mundial de la Salud; 2017.

  8. Sandulescu O. Global distribution of antimicrobial resistance in E. coli. J Contemp Clin Pract. 2016; 2(2):69-74. doi: 10.18683/jccp.2016.1015

  9. Rodríguez J, Gutiérrez B, MachucaI A. Treatment of infections caused by extended-spectrum-betalactamase-,AmpC- and carbapenemase producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31:e00079-17. https://doi.org/10.1128/CMR .00079-17.

  10. Higuita Gutiérrez L, Jiménez Quiceno J. Brotes hospitalarios de bacterias resistentes a colistina: revisión sistemática de la literatura. Infectio. 2017;21(4):214-22.

  11. Legarraga P, Wozniak A, Prado S, Estrella L, García P. Primera comunicación en Chile de la detección del gen mcr-1 en un aislado clínico de Escherichia coli resistente a colistín. Rev Chilena Infectol. 2018;35(4):453-4.

  12. Organización Panamericana de la Salud (OPS). Alerta Epidemiológica: Enterobacterias con resistencia transferible a colistina, implicaciones para la salud publica en las Américas. [Internet] 2016 [acceso: 22/02/2018]. Disponible en: Disponible en: https://www.paho.org

  13. Quiñones D, Carmona Y, Rivero M, Pereda N, Zayas A, Soe M, Kobayashi N. Escherichia coli multidrogorresistente en Cuba: emergencia del clon pandémico ST 131[acceso: 14/07/2020]. Disponible en: Disponible en: http://www.convencionsalud2018.sld.cu

  14. Clinical and Laboratory Standars Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 29th ed. CLSI supplement M100. Wayne, PA. Pennsylvania, USA 2019. [acceso: 22/02/2018]. Disponible en: Disponible en: http://www.clsi.org

  15. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, 2019 [acceso: 23/07/2020]. Disponible en: Disponible en: http://www.eucast.org

  16. Servicio Antimicrobianos del INEI-ANLIS "Dr. Carlos G. Malbrán". Método de elución de discos de colistín. Protocolo adaptado por el Laboratorio Nacional de Referencia [Internet]. 2017.

  17. Menacho O, Candela O J, Garcia Hjarles M. Bacterias patógenas multidrogoresistentes aisladas en estetoscopios de médicos en un hospital de nivel III. Rev Med Hered. 2017;28(3):242-6.

  18. Weiner-Lastinger LM, Abner S, Edwards JR, Kallen AJ, Karlsson M, Magill S, et al. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015-2017. Infect Control Hosp Epidemiol. 2020;4(1):1-18. doi:10.1017/ice.2019.296

  19. Pacheco VM, Gutiérrez D, Serradet M. Vigilancia Epidemiológica de las Infecciones Asociadas a la Asistencia Sanitaria. Rev Ciencias Médicas. 2014;18(3):430-40.

  20. Paris M, Mariño MC, Maceira Z, Castillo A, Leyva E. Caracterización clínica y microbiológica de niños y adolescentes con infecciones asociadas a la atención sanitaria. MEDISAN. Mayo 2018;22(5):508-17.

  21. Ramírez Y, Zayas A, Infante S, Ramírez Y, Mesa I, Montoto V. Infección del sitio quirúrgico en puérperas con cesárea. Rev Cubana Obstet Ginecol [Internet]. Mar 2016 [acceso: 23/07/2020];42(1). Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138-600X2016000100005&lng=es

  22. Salame-Khouri L, Contreras B, Arias S, Mondragón M, Cataneo JL, Núñez M, et al. Epidemiología de las bacteriemias por Escherichia coli en dos hospitales de tercer nivel de la Ciudad de México. An Med (Mex). 2018;63(2):91-5.

  23. Saavedra C, Ordóñez K, Díaz JA. Impacto de la infección nosocomial en un hospital de Bogotá, Colombia. Rev Chilena Infectol. 2015;32(1):25-9.

  24. Suárez B, Milián Y, Espinosa F, Hart M, Llanes N, Martínez ML. Susceptibilidad antimicrobiana y mecanismos de resistencia de Escherichia coli aisladas a partir de urocultivos en un hospital de tercer nivel. Rev Cubana Med. 2014;53(1):3-13.

  25. World Health Organization. Sepsis Technical Expert Meeting - Meeting report. Geneva: WHO; 2018.

  26. Cepero MC, González Y, Madruga MC. Caracterización microbiológica de patógenos bacterianos aislados en aspirados endotraqueales de pacientes con neumonía nosocomial. Panorama Cuba y Salud. 2014;9(2):2-9.

  27. Izydorczyk C, Waddell B, Edwards BD, Greysson-Wong J, Surette MG, Somayaji R, et al. Epidemiology of E. coli in Cystic Fibrosis Airways Demonstrates the Capacity for Persistent Infection but Not Patient-Patient Transmission. Front Microbiol. 2020;11:475.

  28. Bushnell G, Mitrani Gold F, Mundy LM. Emergence of New Delhi metallo ßetalactamase type 1-producing Enterobacteriaceae and non Enterobacteriaceae: Global case detection and bacterial surveillance. Int J Infect Dis. 2013;17:325-33.

  29. Argüez A, Chávez, A. R. y Hernández, N. R. Klebsiella pneumoniae y Escherichia coli productoras de betalactamasas en pacientes con infección del tracto urinario. Rev Cub Med Int Emerg. 2015;14:16-29.

  30. Quiñones D, Soe M, Carmona Y, González MK, Rivero M, Pereda N, et al. High Prevalence of CTX-M Type Extended-Spectrum Beta-Lactamase Genes and Detection of NDM-1 Carbapenemase Gene in Extraintestinal Pathogenic Escherichia coli in Cuba. Pathogens. 2020;9(1):65. Disponible en: http://dx.doi.org/10.3390/pathogens9010065

  31. Tewari R, Mitra S, Ganaie F, Venugopal N, Das S, Shome R, et al. Prevalence of extended spectrum ß-lactamase, AmpC ß-lactamase and metallo ß-lactamase mediated resistance in Escherichia coli from diagnostic and tertiary healthcare centers in south Bangalore. Int J Res Med Sci. Apr 2018;6(4):1308-13.

  32. Quiñones D, Carvajal I, Perez Y, Hart M, Perez J, Garcia S, et al. High prevalence of blaOXA-23 in Acinetobacter spp. and detection of blaNDM-1 in A. soli in Cuba: report from national surveillance Program (2010-2012). New Microbes New Infect. Sep 2015;7: 52-6.

  33. Ortiz Tejedor J. Enterobacterias productoras de carbapenemasas en Cuba, tipos, evaluación de métodos para su detección y antibiotipos. Instituto "Pedro Kourí", 2018 [Tesis Maestría]. La Habana: Instituto de Medicina Tropical "Pedro Kourí"; 2018.

  34. Getenet B, Wondewosen T. Bacterial uropathogens in urinary tract infection and antibiotic susceptibility pattern in Jimma University Specialized Hospital, Southwest Ethiopia. Ethiop J Health Sci. 2011;21(2):141-7.

  35. Mohammad SD, Asghar M, Mohammad SY, Abdolaziz R, Zahra R, Yans Sovan A. Antimicrobial Resistance Trends of Klebsiella spp. Isolated From Patients In Imam Khomeini Hospital. Payavard-Salamat. 2012;6(4):275-81.

  36. Antimicrobial resistance: global report on surveillance. Geneva: World Health Organization; 2014.

  37. Marrero Rodríguez H, Quintero Salcedo S, Blanco Zambrano GL, Duarte Grandales S. Situación de la sepsis intrahospitalaria: subregistro e incumplimiento de las normas higiénico sanitarias establecidas. MEDISAN. 2013;17(3):462-7.

  38. Seok H, Young J, Mi Wi Y, Won Park D, Ran P, Soo Ko K. Fosfomycin Resistance in Escherichia coli Isolates from South Korea and in vitro Activity of Fosfomycin Alone and in Combination with Other Antibiotics. Antibiotics. 2020;9(112):1-13. Disponible en: http://dx.doi.org/10.3390/antibiotics9030112

  39. Melgarejo N, Martínez M, Franco R, Falcón M, Busignani S, Espínola C, et al. Resistencia plasmídica a colistin por el gen mcr-1 en Enterobacteriaceae en Paraguay. Rev Salud Pública Parag. 2018;8(1):44-8.




2020     |     www.medigraphic.com